HomeCompareASLN vs O

ASLN vs O: Dividend Comparison 2026

ASLN yields 333.33% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASLN wins by $3112.21M in total portfolio value
10 years
ASLN
ASLN
● Live price
333.33%
Share price
$0.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3112.25M
Annual income
$1,957,209,378.70
Full ASLN calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — ASLN vs O

📍 ASLN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASLNO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASLN + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASLN pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASLN
Annual income on $10K today (after 15% tax)
$28,333.33/yr
After 10yr DRIP, annual income (after tax)
$1,663,627,971.90/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, ASLN beats the other by $1,663,623,634.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASLN + O for your $10,000?

ASLN: 50%O: 50%
100% O50/50100% ASLN
Portfolio after 10yr
$1556.14M
Annual income
$978,607,240.72/yr
Blended yield
62.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

ASLN
No analyst data
Altman Z
-14.9
Piotroski
3/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASLN buys
0
O buys
0
No recent congressional trades found for ASLN or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASLNO
Forward yield333.33%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$3112.25M$34.2K
Annual income after 10y$1,957,209,378.70$5,102.74
Total dividends collected$3000.20M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: ASLN vs O ($10,000, DRIP)

YearASLN PortfolioASLN Income/yrO PortfolioO Income/yrGap
1← crossover$44,033$33,333.33$10,818$608.16+$33.2KASLN
2$184,291$137,175.49$11,787$741.68+$172.5KASLN
3$733,748$536,556.79$12,946$911.00+$720.8KASLN
4$2,781,635$1,996,524.01$14,345$1,127.94+$2.77MASLN
5$10,050,002$7,073,652.70$16,056$1,409.05+$10.03MASLN
6$34,638,543$23,885,041.43$18,171$1,777.83+$34.62MASLN
7$114,000,322$76,937,080.16$20,820$2,268.21+$113.98MASLN
8$358,625,914$236,645,569.53$24,188$2,929.90+$358.60MASLN
9$1,079,474,884$695,745,156.26$28,533$3,837.11+$1079.45MASLN
10$3,112,247,504$1,957,209,378.70$34,235$5,102.74+$3112.21MASLN

ASLN vs O: Complete Analysis 2026

ASLNStock

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Full ASLN Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this ASLN vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASLN vs SCHDASLN vs JEPIASLN vs KOASLN vs MAINASLN vs STAGASLN vs ADCASLN vs NNNASLN vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.